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Serosurvey of Human Metapneumovirus Infection in Croatia
Aim. To assess the seroprevalence of human metapneumovirus 
(hMPV) in Croatia.
Methods. During 2005, a total of 137 serum specimens from Croatian 
patients aged from 6 days to 51 years, without respiratory symptoms, 
were collected at the Croatian National Institute of Public Health. The 
sera were examined using the indirect immunofluorescent assay.
Results. The overall hMPV seropositivity rate in the samples tested was 
77.4% (106/137). The seropositivity rate increased from 18.7% in chil-
dren aged between 6 months and 1 year to 100% in people older than 
20 years of age. The highest proportion of titers ≥1:512 was found in 
children aged from 1 to 2 years.
Conclusion. Our results suggest that hMPV infection is present in 
Croatia, with primary infection occurring in early childhood. This is 
the first study that indicates the circulation of hMPV in Croatia.
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Human metapneumovirus (hMPV) is a newly discovered re-
spiratory virus assigned to the Paramyxoviridae family, Pneu-
movirinae subfamily, Metapneumovirus genus. It was first 
isolated in 2001 from nasopharyngeal aspirates obtained from 
young children in the Netherlands (1). Sequence analysis of 
several isolates identified two major genetic lineages (subtypes 
A and B) that can be further divided into subgroups A1, A2, 
B1, and B2 (2). HMPV causes acute respiratory tract infec-
tions in all age groups (3,4). In hospitalized young children, 
hMPV infection is commonly present as bronchiolitis with or 
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without pneumonitis (5,6), whereas bronchitis, 
bronchospasm, and pneumonitis are most com-
monly seen in elderly patients (3). Since the ini-
tial report, hMPV has been studied all over the 
world and it has been reported on all continents 
(7). Seroprevalence surveys from the Nether-
lands (1), Japan (8), and Israel (9) indicated that 
virtually all children are infected by 5-10 years of 
age. The aim of this study was to demonstrate the 
presence of hMPV infection in Croatia, by ex-
amining sera from Croatian people for specific 
anti-hMPV antibodies by an indirect immuno-
fluorescent assay (IFA).
Materials and methods
Serum samples
A total of 137 serum specimens from Croatian 
patients aged from 6 days to 51 years were exam-
ined at the Croatian National Institute of Pub-
lic Health (CNIPH). The study was conduct-
ed as a part of the project “Disease Agents with 
Droplet Route of Spread,” approved by the Eth-
ic Committees of Croatian National Institute of 
Public Health, University Children’s Hospital 
Zagreb, and University Hospital for Infectious 
Diseases. The sera from patients with a diagnosis 
of acute respiratory infection were excluded. The 
test samples were randomly selected from a bank 
of specimens collected from January 1 to Decem-
ber 31, 2005 from patients visiting the CNIPH 
for neurological (20%), lymphatic (35%), and 
skin disorders (15%), as well as various other di-
agnoses, such as hepatic lesions, myocarditis, and 
thrombocytopenia (30%). Serum samples were 
divided into six groups, according to the pa-
tient’s age: 0-6 months (n = 21), >6 months to 
1 year (n = 16), >1-2 years (n = 11), >2-5 years 
(n = 20), >5-20 years (n = 45), and >20 years 
(n = 24).
Antigen preparation
LLC-MK2 cells (rhesus monkey kidney, Euro-
pean Collection of Cell Cultures, Feltham, UK) 
were grown in cell culture medium, consisting of 
minimal essential medium (MEM; Invitrogen, 
Paisley, UK), supplemented with 10% fetal bo-
vine serum (Invitrogen, Paisley, UK). When the 
cell monolayer reached almost 100% confluen-
cy, cells were rinsed with phosphate-buffered sa-
line (PBS) and infected with hMPV with addi-
tion of trypsin (Sigma-Aldrich, Saint Louis, MO, 
USA) in concentration of 1 μg/mL. HMPV iso-
late CAN97-83/A strain was kindly provided by 
Dr Guy Boivin, Centre de Recherche en Infec-
tologie, Ste-Foy (Quebec), Canada. When cy-
topathic effect was evident, cells were dried and 
fixed on glass slides as previously described by 
Ebihara et al (8).
HMPV-infected cells were confirmed by IFA, 
using mouse monoclonal antibodies against nu-
cleocapsid (N) and fusion (F) protein of hMPV, 
which reacts both against A and B hMPV geno-
types prepared at Rochester General Hospital, 
University of Rochester School of Medicine and 
Dentistry, Rochester, NY, USA (Figure 1A). 
Mock-infected cells were used as negative con-
trol (Figure 1B).
Figure 1. Detection of human metapneumovirus in an indirect immunofluorescent assay. A) positive control (hMPV-infected cells recognized by 
monoclonal antibodies against N protein of hMPV, KE11-3); B) negative control (mock-infected cells); C) reaction with a positive serum sample.
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Indirect immunofluorescence assay
Serum specimens were analyzed for the presence 
of anti-hMPV antibodies using IFA in the fol-
lowing way. Sera were diluted serially, beginning 
at 1:8. After incubation of sera with fixed cells 
at 37°C for 30 minutes, the slides were washed 
three times in PBS for 10 minutes. The slides 
were then incubated in the same conditions 
with commercial, mixed IFA conjugate consist-
ing of goat antihuman IgA, IgG, and IgM anti-
bodies conjugated with fluorescein isothiocya-
nate (Virion, Rüschlikon, Zürich, Switzerland). 
Green fluorescence was observed in the cyto-
plasm and on cell surface, but absent in the nu-
cleus of the cells (Figure 1C). Sera that reacted 
to hMPV antigens at dilution equal or more 
than 1:8 were considered positive for hMPV an-
tibodies.
Statistical analysis
Statistical analysis was performed by Fisher ex-
act test using STATISTICA for Windows (Stat-
Soft, Inc. Tulsa, OK, USA). P value <0.05 was 
considered to be significant.
Results
All 137 patients were Caucasians between 6 days 
to 51 years old. There were 74 men and 63 wom-
en. Overall 77.4% (106/137) of the samples test-
ed were positive for hMPV antibodies. The se-
ropositivity rate increased from 18.7% (3/16) 
in children aged between 6 months and 1 year 
to 45.5% (5/11) in children aged between 1 and 
2 years, and 88.9% (40/45) in subjects aged 5-
20 years. In this study, all subjects (24/24) older 
than 20 years had anti-hMPV antibodies (Figure 
2). Statistical analysis by Fisher exact test showed 
that antibody prevalence was significantly lower 
in the age group from 6 months to 1 year, com-
pared with antibody prevalence in all groups old-
er than 2 years (P<0.001), but was not signifi-
cantly different from the 1-2-year old age group 
(P = 0.206). Of the seropositive subjects, the pro-
portion with titers ≥1:512 in the age groups 1-2 
years, 2-5 years, and 5-20 years was 40% (2/5), 
5.9% (1/17), and 5.0% (2/40), respectively (Fig-
ure 2). The difference between the 1-2-year group 
and the 5-20-year group was statistically signifi-
cant (P = 0.024).
Discussion
The hMPV seropositivity rate in Croatian indi-
viduals of 77.4% found in our study is similar to 
the rate found in a Japanese serologic study per-
formed in 2003 (8) on patients without respi-
ratory symptoms and in Uruguayan study from 
2005 (10) performed on healthy donor adults 
and children without any underlying patholo-
gy. In these studies, hMPV seropositivity rates 
were reported to be 72.5% and 80%, respective-
ly. The seropositivity rate of 100% was found in 
the population of subjects older than 20 years, 
in contrast to Dutch and Japanese studies where 
hMPV seroprevalence reached 100% in the 5-10 
age group (1,8). In addition, the results of sero-
logic tests performed in the Netherlands showed 
that 25% of infants aged 6 months to 1 year 
were seropositive, increasing to 55% in children 
1-2 years old and 70% in those 2-5 years old. 
Our study demonstrated slightly lower sero-
prevalence in the first two age groups (18.7%, 
Figure 2. Seroprevalence and antibody titers of human metapneumovirus in Croatia. 
Open bars – negative; dotted bars – 1:8; bars with horizontal lines  – 1:16; bars with 
vertical lines – 1:32; bars diagonal lines – 1:64; grid bars – 1:128; gray bars – 1:256; 
closed bars – 1:512.
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45.5%) and a higher seroprevalence in the 2-5 
age group (85%).
In our study, 17 of 21 infants under 6 months 
of age (81%) had hMPV antibodies suggesting 
the presence of transplacentally derived maternal 
antibodies. In accordance with this is the lowest 
prevalence of 18.7%, found in the age group be-
tween 6 months and 1 year, when maternal anti-
bodies would be expected to be at their nadir.
Seroprevalence increased with age consistent 
with increased exposure to hMPV. High titers 
of hMPV specific antibodies indicate recently 
acquired infection. Therefore, the highest pro-
portion of titers ≥1:512 was found in the1-2 age 
group, when infants lack transplacentally derived 
maternal antibodies and are exposed to hMPV 
(this may be largely IgM). These findings indicate 
that the most of hMPV primary infections occur 
in early childhood (1-2 years of age).
Our results suggest that hMPV infection is 
present in Croatia, confirming the previous re-
ports of hMPV worldwide distribution (7).
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